Literature DB >> 20560471

[Human renal urate transpoter URAT1 mediates the transport of salicylate].

Naoko Ohtsu1, Naohiko Anzai, Toshiyuki Fukutomi, Toru Kimura, Hiroyuki Sakurai, Hitoshi Endou.   

Abstract

Salicylic acid derivatives are the most prescribed analgesic-antipyretic and anti-inflammatory agents. It is well known that salicylate has a paradoxical effect on renal urate excretion. At low doses (5 - 10 mg/dL serum), renal urate excretion is decreased, whereas at high doses (> 15 mg/dL serum), renal urate excretion is increased. Since the molecular identification of the renal apical urate/anion exchanger URAT1, it has been suggested that this protein is responsible for the paradoxical effect because of cis-inhibition of salicylate (1 mM) on urate uptake by URAT1-expressing oocytes. The purpose of this study was to examine whether or not URAT1 is responsible for the paradoxical effect of salicylate. In URAT1-stably expressing HEK293 (HEK293-URAT1) cells, salicylate inhibited [14C] urate uptake dose-dependently (IC50, 23.9 microM). URAT1 mediated the time-dependent uptake of [3H] salicylate in these cells. [3H] Salicylate uptake via URAT1 was inhibited by non-labelled urate and salicylate, and the uricosuric agent, benzbromarone. In the URAT1-expressing oocytes, we observed the time- and concentration-dependent transport of salicylate (Km : 25.3 microM). Moreover, non-labelled salicylate injected into the URATI-expressing oocytes stimulated [14C] urate uptake. These results suggest that the "paradoxical effect" of salicylate can be explained by two modes of salicylate interaction with URAT1 : (1) acting as an exchange substrate to facilitate urate reabsorption, and (2) acting as an inhibitor for urate reabsorption.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560471

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  6 in total

Review 1.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

Review 2.  Urate Handling in the Human Body.

Authors:  David Hyndman; Sha Liu; Jeffrey N Miner
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia.

Authors:  Liting Wu; Yingchao Fan; Yuan Wang; Zhumeng Li; Delong Mao; Wenfang Zhuang
Journal:  J Clin Lab Anal       Date:  2021-09-08       Impact factor: 2.352

Review 4.  Modulation of Urate Transport by Drugs.

Authors:  Péter Tátrai; Franciska Erdő; Gabriella Dörnyei; Péter Krajcsi
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

Review 5.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

6.  Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma.

Authors:  Jiaju Xu; Yuenan Liu; Jingchong Liu; Yi Shou; Zhiyong Xiong; Hairong Xiong; Tianbo Xu; Qi Wang; Di Liu; Huageng Liang; Hongmei Yang; Xiong Yang; Xiaoping Zhang
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.